Product Description
Desvenlafaxine is used to treat depression. Desvenlafaxine is in a class of medications called selective serotonin and norepinephrine reuptake inhibitors (SNRIs). It works by increasing the amounts of serotonin and norepinephrine, natural substances in the brain that help maintain mental balance. (Sourced from: https://medlineplus.gov/druginfo/meds/a608022.html)
Mechanisms of Action: SNR Inhibitor
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: None *
Approval Status: Approved
Approved Countries: Argentina | Australia | Austria | Bangladesh | Brazil | Canada | Chile | Colombia | Dominican Republic | Ecuador | Egypt | Germany | Hong Kong | India | Ireland | Italy | Jordan | Korea | Malaysia | Mexico | Pakistan | Peru | Philippines | Portugal | Saudi Arabia | Serbia | Singapore | South Africa | Spain | Thailand | Ukraine | United Arab Emirates | United States | Uruguay | Vietnam
Approved Indications: Depressive Disorder | Depressive Disorder, Major
Known Adverse Events: Dizziness | Insomnia | Hyperhidrosis | Constipation
Company: Pfizer
Company Location: NEW YORK NY 10017
Company CEO: Albert Bourla
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic: China, Japan
Active Clinical Trial Count: 5
Highest Development Phases
Phase 3: Depressive Disorder|Depressive Disorder, Major
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| JapicCTI-205252 | P3 |
Active |
Unknown |
2022-12-31 |
|
| jRCT2080225156 | P3 |
Completed |
Depressive Disorder, Major |
2022-12-31 |
|
| MD120101 | P3 |
Completed |
Depressive Disorder, Major |
2022-07-21 |
|
| 2008-002064-34 | P3 |
Active, not recruiting |
Depressive Disorder, Major |
2019-05-15 |